Samsung BioLogics Archives | Page 5 of 5

Home / Posts tagged Samsung BioLogics (Page 5)

Samsung Bioepis Wins Approval to Sell Biosimilar in South Korea

SEOUL, Sept. 20 (Korea Bizwire) – Samsung Biologics Co. said Wednesday its affiliate Samsung Bioepis Co. won a nod from South Korea’s drug agency to sell its biosimilar dubbed SB5. Through the approval granted by the Ministry of Food and Drug Safety, Samsung Biologics said in a regulatory filing that the biosimilar is ready for sale in the country. The SB5 is a biosimilar of Humira released by U.S.-based AbbVie Inc., used for the treatment of various diseases including Crohn’s [...]

Samsung BioLogics Tops Swiss Drug Giant Lonza in Market Cap

SEOUL, Sept. 20 (Korea Bizwire) — South Korean biopharmaceutical maker Samsung BioLogics Co. has overhauled Swiss drug behemoth Lonza in terms of market value though its sales remain dwarfed by the latter’s top line, industry sources said Wednesday. The market capitalization of Samsung BioLogics, a unit of South Korea’s top conglomerate Samsung Group, came to [...]

Samsung BioLogics Suffers Operating Loss During Second Quarter

SEOUL, July 24 (Korea Bizwire) – Samsung BioLogics, a biopharmaceutical unit of South Korea’s top conglomerate Samsung Group, suffered a loss in the second quarter despite a rise in sales, the company said Monday. Sales jumped 33 percent on-year to 63.2 billion won (US$57 million) during the April-June period, the company said in a regulatory [...]

Samsung BioLogics Suffers Loss in 2016

SEOUL, Jan. 24 (Korea Bizwire) – Samsung BioLogics, a biopharmaceutical unit of South Korea’s top conglomerate Samsung Group, suffered a loss last year despite a sharp rise in sales, the company said Tuesday. Sales more than tripled to 295 billion won (US$252.6 million) in 2016 from 91.28 billion the previous year, the company said in [...]

S. Korea’s Biomedicine Exports Top US$1 Bln in 2016: Data

SEOUL, Jan. 18 (Korea Bizwire) – Biomedicine exports by South Korean pharmaceutical firms jumped more than 50 percent in 2016 from a year earlier to surpass the US$1 billion mark for the first time, data showed Wednesday. Outbound shipments of locally manufactured biomedicines such as vaccines and genetic recombination drugs stood at US$1.44 billion last [...]

Samsung BioLogics Makes Strong Market Debut

SEOUL, Nov. 10 (Korea Bizwire) – Shares of Samsung BioLogics, a biopharmaceutical unit of Samsung Group, made a strong market debut on Thursday trading above its initial public offering price. Samsung BioLogics was changing hands at 136,500 won (US$118) as of 9:20 a.m., above the IPO price of 136,000 won. Its market capitalization was some [...]

Mega IPOs May Help Shore up Sagging Stock Market

SEOUL, Nov. 3 (Korea Bizwire) — Samsung BioLogics, a biopharmaceutical unit of Samsung Group, and Doosan Bobcat Co., an affiliate of power equipment conglomerate Doosan Group, are set to make their market debuts this month, which some analysts say may help the local stock market recover from a recent market turmoil. Last week, Samsung BioLogics, [...]

Samsung BioLogics Set to Start IPO Process This Week

SEOUL, Aug. 8 (Korea Bizwire) – Samsung BioLogics Co., a biosimilar firm affiliated with Samsung Group, will apply for preliminary approval this week for its initial public offering (IPO), estimated at around 3 trillion won (US$2.68 billion), South Korea’s bourse said Monday. The firm, one of the world’s largest manufacturers of biosimilar medicine, plans to [...]

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

NEW YORK & SEOUL, South Korea, Apr. 22, 2014 (Korea Bizwire) – Bristol-Myers Squibb Company (NYSE:BMY) and Samsung BioLogics announced the companies will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site. Financial terms of the [...]